A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF)

McMurray, J. J.V. et al. (2019) A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF). European Journal of Heart Failure, 21(5), pp. 665-675. (doi:10.1002/ejhf.1432) (PMID:30895697) (PMCID:PMC6607736)

[img]
Preview
Text
205256.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

646kB

Abstract

Background: Sodium–glucose co‐transporter 2 (SGLT2) inhibitors have been shown to reduce the risk of incident heart failure hospitalization in individuals with type 2 diabetes who have, or are at high risk of, cardiovascular disease. Most patients in these trials did not have heart failure at baseline and the effect of SGLT2 inhibitors on outcomes in individuals with established heart failure (with or without diabetes) is unknown. Design and methods: The Dapagliflozin And Prevention of Adverse‐outcomes in Heart Failure trial (DAPA‐HF) is an international, multicentre, parallel group, randomized, double‐blind, study in patients with chronic heart failure, evaluating the effect of dapagliflozin 10 mg, compared with placebo, given once daily, in addition to standard care, on the primary composite outcome of a worsening heart failure event (hospitalization or equivalent event, i.e. an urgent heart failure visit) or cardiovascular death. Patients with and without diabetes are eligible and must have a left ventricular ejection fraction ≤ 40%, a moderately elevated N‐terminal pro B‐type natriuretic peptide level, and an estimated glomerular filtration rate ≥ 30 mL/min/1.73 m2. The trial is event‐driven, with a target of 844 primary outcomes. Secondary outcomes include the composite of total heart failure hospitalizations (including repeat episodes), and cardiovascular death and patient‐reported outcomes. A total of 4744 patients have been randomized. Conclusions: DAPA‐HF will determine the efficacy and safety of the SGLT2 inhibitor dapagliflozin, added to conventional therapy, in a broad spectrum of patients with heart failure and reduced ejection fraction.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Petrie, Professor Mark and McMurray, Professor John
Authors: McMurray, J. J.V., DeMets, D. L., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Langkilde, A. M., Martinez, F. A., Bengtsson, O., Ponikowski, P., Sabatine, M. S., Sjöstrand, M., Solomon, S. D., Diez, M., Nicolau, J., Katova, T., O'Meara, E., Howlett, J., Verma, S., Ge, J., Belohlavek, J., Schou, M., Böhm, M., Merkely, B., Chopra, V., Kitakaze, M., de Boer, R. A., Drozdz, J., Tereshchenko, S., Dukat, A., Ljungman, C., Chiang, C.‐E., Petrie, M., Desai, A., Anand, I., Pham, V. N., Pfeffer, M. A., Pocock, S., Swedberg, K., Rouleau, J. L., Chaturvedi, N., Ivanovich, P., Levey, A. S., Christ‐Schmidt, H., Held, C., Varenhorst, C., Christersson, C., Mann, J., Holmgren, P., Hallberg, T., Langkilde, A., Sjöstrand, M., Denison, H., Reicher, B., Bengtsson, O., Fox, Y., Forsby, M., Alenhag, E.‐L., Nilsson, A., Kazanowska, K., Olofsson, E. L., Karup, C., Ekedahl‐Berggren, M., Klockargård, A.‐L., Kempe, K., and Selvén, M.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
Journal Name:European Journal of Heart Failure
Publisher:Wiley
ISSN:1388-9842
ISSN (Online):1879-0844
Published Online:21 March 2019
Copyright Holders:Copyright © 2019 The Authors
First Published:First published in European Journal of Heart Failure 21(5):665-675
Publisher Policy:Reproduced under a Creative Commons license

University Staff: Request a correction | Enlighten Editors: Update this record